Needham Maintains Their Hold Rating on Regulus (RGLS)

In a report released today, Alan Carr from Needham maintained a Hold rating on Regulus (RGLS). The company’s shares closed last Friday at $0.50, close to its 52-week low of $0.42.

According to TipRanks.com, Carr is a 3-star analyst with an average return of 1.5% and a 43.0% success rate. Carr covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Lexicon Pharmaceuticals, and Crispr Therapeutics AG.

Currently, the analyst consensus on Regulus is a Moderate Buy with an average price target of $1.25.

See today’s analyst top recommended stocks >>

Based on Regulus’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $6.95 million. In comparison, last year the company earned revenue of $18K and had a GAAP net loss of $5.02 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Regulus Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in September 2007 and is headquartered in San Diego, CA.